Browsing by Author "Daniels, Anthony B."

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Aqueous VEGF-A Levels as a Liquid Biopsy Biomarker of Retinoblastoma Vitreous Seed Response to Therapy
    (Association for Research in Vision and Ophthalmology, 2024) Daniels, Anthony B.; Sishtla, Kamakshi L.; Bogan, Carley M.; Pierce, Janene M.; Chen, Sheau-Chiann; Xu, Liya; Berry, Jesse L.; Corson, Timothy W.; Pharmacology and Toxicology, School of Medicine
    Purpose: Regression of retinoblastoma vitreous seeds (VS) during intravitreal chemotherapy can be delayed, resulting in supernumerary injections. Similarly, VS relapse may not be clinically evident at first. A predictive biomarker of tumor regression and relapse could help guide real-time clinical decision making. Retinoblastoma is an oxygen-sensitive tumor; paradoxically, VS survive in the hypoxic vitreous. We hypothesized that VS elaborate pro-angiogenic cytokines. The purpose was to determine if pro-angiogenic cytokine signatures from aqueous humor could serve as a biomarker of VS response to treatment. Methods: Multiplex ELISA was performed on aqueous from rabbit eyes with human retinoblastoma VS xenografts to identify expressed proangiogenic cytokines and changes in aqueous cytokine levels during intravitreal treatment were determined. Confirmatory RNAscope in situ hybridization for VEGF-A was performed on human retinoblastoma tumor sections and VS xenografts from rabbits. For human eyes undergoing intravitreal chemotherapy, serial aqueous VEGF-A levels measured via VEGF-A-specific ELISA were compared to clinical response. Results: VEGF-A was highly expressed in human retinoblastoma VS in the xenograft model, and was the only proangiogenic cytokine that correlated with VS disease burden. In rabbits, aqueous VEGF-A levels decreased in response to therapy, consistent with quantitative VS reduction. In patients, aqueous VEGF-A levels associated with clinical changes in disease burden (regression, stability, or relapse), with changes in VEGF-A levels correlating with clinical response. Conclusions: Aqueous VEGF-A levels correlate with extent of retinoblastoma VS, suggesting that aqueous VEGF-A may serve as a predictive molecular biomarker of treatment response.
  • Thumbnail Image
    Item
    Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease
    (SpringerLink, 2021-07) Chahoud, Jad; McGettigan, Melissa; Parikh, Nainesh; Boris, Ronald S.; Iliopoulos, Othon; Rathmell, W. Kimryn; Daniels, Anthony B.; Jonasch, Eric; Spiess, Philippe E.; Urology, School of Medicine
    This brief report focuses on the evaluation and diagnosis of clinically localized renal masses in children and adults with Von Hippel–Lindau (VHL) disease. Counseling considerations pertinent to the urologists, medical oncologists, and multidisciplinary teams involved in the care of these patients are addressed. As practice patterns regarding the evaluation and management of VHL tumors can vary considerably, this report aims to provide guidance on some of the controversies associated with the diagnostic evaluation and initial management of localized renal masses in VHL patients.
  • Thumbnail Image
    Item
    An international survey of classification and treatment choices for group D retinoblastoma
    (IJO Press, 2017-06-18) Scelfo, Christina; Francis, Jasmine H.; Khetan, Vikas; Jenkins, Thomas; Marr, Brian; Abramson, David H.; Shields, Carol L.; Pe’er, Jacob; Munier, Francis; Berry, Jesse; Harbour, J. William; Yarovoy, Andrey; Lucena, Evandro; Murray, Timothy G.; Bhagia, Pooja; Paysse, Evelyn; Tuncer, Samuray; Chantada, Guillermo L.; Moll, Annette C.; Ushakova, Tatiana; Plager, David A.; Ziyovuddin, Islamov; Leal, Carlos A.; Materin, Miguel A; Ji, Xun-Da; Cursino, Jose W.; Polania, Rodrigo; Kiratli, Hayyam; All-Ericsson, Charlotta; Kebudi, Rejin; Honavar, Santosh G.; Vishnevskia-Dai, Vicktoria; Epelman, Sidnel; Daniels, Anthony B.; Ling, Jeanie D.; Traore, Fousseyni; Ramirez-Ortiz, Marco A.; Pediatrics, School of Medicine
    AIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Children's Hospital of Los Angeles (CHLA) version, 33% used the Children's Oncology Group (COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center (P<0.0001). CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.